Insider transactions

Patrick J Heron

CIK 1365617 · last filed 2026-06-17

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$570.42M
Companies
16
Total Filings
71
Lifetime Open-Market Net
$87.63M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

ETTX price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
550 HAMILTON AVE., SUITE 100
PALO ALTO, CA 94301
Related Filers
James N Topper — 23 joint filings, latest 2025-09-30
FHM LIFE SCIENCES VIII, L.L.C. — 13 joint filings, latest 2023-10-26
Frazier Life Sciences VIII, L.P. — 13 joint filings, latest 2023-10-26
Nathan R Every — 12 joint filings, latest 2018-05-15
Alan D Frazier — 12 joint filings, latest 2018-05-15
Nader J Naini — 12 joint filings, latest 2018-05-15
FHMLS X, L.L.C. — 9 joint filings, latest 2025-09-30
Frazier Life Sciences X, L.P. — 9 joint filings, latest 2025-09-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MIRM Director 464,713 $82.97 $38.56M $20.35M 19 2026-06-17
ARQT Director 59,661 $31.86 $1.90M $9.07M 16 2026-06-12
MBX Director 3,927,774 $50.69 $199.10M $10.00M 4 2026-06-05
HilleVax, Inc. (HLVX) Delisted Director 8,552,536 $2.09 $17.87M $0 4 2025-06-25
Imago BioSciences, Inc. (IMGO) Delisted Director — $36.01 — $0 1 2021-07-19
PCVX Director 2,309,554 $60.25 $139.15M $4.00M 3 2021-06-03
Iterum Therapeutics plc (ITRM) Delisted Director 80,411 $0.03 $2.4K $0 5 2020-07-06
PASG Director 148,862 $3.31 $492.7K $9.90M 2 2020-03-03
Entasis Therapeutics Holdings Inc. (ETTX) Delisted 10%+ Owner 1,299,953 $2.19 $2.85M $21.30M 2 2020-01-13
ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted 10%+ Owner 2,571,450 $64.97 $167.07M $8.00M 1 2019-01-22
ANAB 10%+ Owner 3,319,224 $49.24 $163.46M $0 2 2018-05-15
Tobira Therapeutics, Inc. (TBRA) Delisted Director 2,668,570 — — $0 3 2016-01-14
COLL Director 1,196,834 $23.20 $27.76M $1.80M 2 2015-09-14
GKOS 10%+ Owner — $182.24 — $0 1 2015-06-30
Cidara Therapeutics, Inc. (CDTX) Delisted Director 7,782 $221.38 $1.72M $3.20M 1 2015-04-22
Trubion Pharmaceuticals, Inc (TRBN) Delisted Director 0 — — $0 4 2010-10-28

Recent Filings · Page 6 of 8

71 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-01-13 Entasis Therapeutics Holdings Inc. (ETTX) Delisted Sell (S) −250,000 -$1.25M EDGAR
2019-07-24 MIRM Mixed +3,566,912 $6.75M EDGAR
2019-06-17 Iterum Therapeutics plc (ITRM) Delisted Grant (A) — $0 EDGAR
2019-05-29 Iterum Therapeutics plc (ITRM) Delisted Exer (M) +6,154 $0 EDGAR
2019-01-22 ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted Buy (P) +1,489,756 $8.00M EDGAR
2018-10-02 Entasis Therapeutics Holdings Inc. (ETTX) Delisted Mixed +5,143,916 $22.55M EDGAR
2018-05-29 Iterum Therapeutics plc (ITRM) Delisted Grant (A) — $0 EDGAR
2018-05-15 ANAB Other (J) −9,604,000 $0 EDGAR
2017-02-06 ANAB Exer (X) +937,880 $4.27M EDGAR
2016-11-03 — Disp (D) — $0
Showing 51–60 of 71
Page 6 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.